Bratisl Lek Listy. 2024;125(11):724-727. doi: 10.4149/BLL_2024_110.
Pancreatic carcinoma is one of the most severe oncological diseases of the gastrointestinal tract. At the time of diagnosis, up to 28% of patients have metastatic liver damage, and only 5% of patients survive five years. Scientific research focuses on non-invasive markers that could help screen for the disease and identify patients more quickly. Potential biomarkers also include matrix metalloproteinases, which play a role in oncogenesis.
We prospectively followed 46 patients with pancreatic cancer and benign pancreatic diseases from September 2022 to March 2023. We determined the level of MMP9 in serum and tissue biopsied during surgeries.
As a result, MMP9 levels were elevated from the T2 stage. The correlation between disease stage and MMP9 level was not confirmed in lower stages, possibly due to the small group of patients.
MMP9 seems suitable for detecting late stages of pancreatic cancer, possibly for secondary prevention. We could not confirm a correlation between MMP9 levels and the initial stages of the disease (Tab. 1, Fig. 3, Ref. 21). Text in PDF www.elis.sk Keywords: pancreatic cancer, MMP9, marker, non-invasive, screening.
胰腺癌是最严重的胃肠道肿瘤学疾病之一。在诊断时，多达 28%的患者有肝转移损伤，只有 5%的患者能存活五年。科学研究集中在非侵入性标志物上，这些标志物可能有助于筛查疾病，并更快地识别患者。潜在的生物标志物还包括基质金属蛋白酶，其在肿瘤发生中起作用。
我们前瞻性地随访了 46 名患有胰腺癌和良性胰腺疾病的患者，随访时间为 2022 年 9 月至 2023 年 3 月。我们在手术期间确定了血清和组织活检中 MMP9 的水平。
结果显示，MMP9 水平从 T2 期开始升高。在较低的分期中，疾病分期和 MMP9 水平之间的相关性未得到证实，这可能是由于患者人数较少。
MMP9 似乎适合检测晚期胰腺癌，可能用于二级预防。我们无法证实 MMP9 水平与疾病的初始阶段之间存在相关性（表 1，图 3，参考文献 21）。
